Introduction {#Sec1}
============

T-cell prolymphocytic leukemia (T-PLL) is an aggressive lymphoproliferative disorder that represents in 2% of all mature lymphocytic leukemias in adults; also it has been classified as an aggressive subtype of chronic lymphocytic leukemia (CLL) \[[@CR1]\]. T-PLL causes major problems due to negative effects on the immune system, thus predisposing the affected patient to a variety of infections, and possibly death \[[@CR2]\]. T-PLL affects mainly adults (median age 61 years) and is more common in male (male/female =2:1) \[[@CR3]\].

T-PLL characterized by several clinical features like splenomegaly (75% of patients), generalized lymphadenopathy (50%), and skin infiltration (25%) with skin nodules, maculopapular rash, or more rarely erythroderma. Also serous effusions, particularly pleural effusions (15%) are regularly seen \[[@CR4], [@CR5]\]. The majority of T-PLL patients present with severely increased lymphocyte count (\>100,000/μl). Anemia and thrombocytopenia are present in half of the patients, and lactate dehydrogenase (LDH) levels are usually elevated \[[@CR6]\]. The clinical course of the disease is usually aggressive, with poor or no response to therapy \[[@CR7]\].

The immunophenotype of T-PLL cells resembles that of mature post-thymic T-cells with expression of CD2, CD3, and CD7. The T-cell receptor (TCR) beta/gamma genes can be clonally rearranged \[[@CR1]\]. The most frequent chromosomal abnormalities in T-PLL include 14q11.2-aberrations, chromosome 8 rearrangements and/or 11q abnormalities, the latter leading to the deletion of the ataxia-telangiectasia mutated (*ATM*) and mixed lineage leukemia (*MLL*) genes, as well as abnormalities e.g. in 5q, 6q, 9p, 12p, and 13q \[[@CR8]--[@CR11]\].

Here we report an untreated childhood T-PLL case with do novo del(9)(p13) as sole abnormality, which leads to monoallely of tumor suppressor gene *CDKN2A* (cyclin-dependent kinase inhibitor 2A).

Material and methods {#Sec2}
====================

Case report {#Sec3}
-----------

A 16 year old male patient without significant personal or familial medical chronically presented with a 1 month history of dyspnea, fatigue, loss of weight, fever and pleural effusion in right lung. Pleural fluid examination revealed an elevated white blood cell (WBC) count of 218.4 × 10^9^/l (70% were lymphocytes and 15% were blasts), and LDH level of 3,486 U/l (normal up to 480 U/l). On physical examination enlarged liver was suggested whereas, CT scan and echography of the abdomen revealed normal liver size; several skin nodules (1--2 cm) in different locations such as neck, mandible and armpit were detected (data not shown). Routine peripheral blood test showed WBC count of 70.6 × 10^9^/l (74.6% were lymphocytes). The red blood cell (RBC) count was 4.52 × 10^6^/mm^3^ with a hemoglobin level of 11.8 g/dl and platelets count of 0.277 × 10^9^/l. Biochemistry analyses revealed LDH level of 1,377 U/l; alanine aminotransferase (ALT) level was 142 U/l (normal up to 40U/l); aspartate aminotrasferase (AST) level 51 U/l (normal up to 40U/l); total serum protein 6 g/dl (normal 6.4-8.3 g/dl); serum albumin 4 g/dl (normal 3.5-5.2 g/dl); and serum calcium value 9.7 mg/dl (normal 8.5-10.5 mg/dl). Bone marrow smear showed approximately 95% of cells were blasts. Unfortunately the patient died two months after diagnosis from the disease due to respiratory arrest.

Cytogenetic analysis {#Sec4}
--------------------

Cytogenetic analysis using GTG-banding was performed according to standard procedures \[[@CR12]\]. A minimum of 20 metaphase cells derived from unstimulated bone marrow culture were analyzed. Karyotypes were described according to the International System for Human Cytogenetic Nomenclature (ISCN 2009).

Molecular cytogenetics {#Sec5}
----------------------

FISH using a whole chromosome painting (WCP) probe for chromosome 9 (MetaSystems/Germany) and a locus specific probe for *CDKN2A* gene (LSI p16 in 9p21) with a probe for centromere 9 (Abbott Molecular/Vysis, Abbott Park, IL, USA) were applied according to manufacturer's instructions \[[@CR12]\]. Also a multicolor banding probe (MCB) sets based on microdissection derived region-specific libraries for chromosome 9 was applied as previously described \[[@CR13]\]. A minimum of 20 metaphase spreads were analyzed, using a fluorescence microscope (AxioImager.Z1 mot, Carl Zeiss Ltd., Hertfordshir, UK) equipped with appropriate filter sets to discriminate between a maximum of five fluorochromes plus the counterstain DAPI (4\',6- diamino-2-phenylindole). Image capture and processing were performed using an ISIS imaging system (MetaSystems).

Flow cytometry {#Sec6}
--------------

Flow cytometry of leukemic blasts was performed using a general panel of fluorescent antibodies against the following antigens typical for different cell lineages and cell types: CD1a, CD2, CD3, CD4, CD5, CD8, CD10, CD11b, CD11c, CD13, CD14, CD15, CD16, CD19, CD20, CD22, CD23, CD32, CD33, CD34, CD38, CD41a, CD45, CD56, CD57, CD64, CD103, CD117, CD123, CD209, CD235a and CD243; in addition antibodies against Kappa and Lambda light Chains, sIgD, sIgM, and HLADr were applied (BD Biosciences). Four-color immunophenotyping on peripheral blood specimen was performed. Samples were stained and analyzed on a BD FACSCalibur™ flow cytometer according to BD Biosciences manuals and products insert sheets. Autofluorescence, viability, and isotype controls were included. Flow cytometric data acquisition and analysis were conducted by BD Cellquest™ Pro software.

Results {#Sec7}
=======

Karyotyping was performed before initiation of any treatment and GTG banding revealed a karyotype of 46,XY,del(9)(p?) (20) (Figure [1](#Fig1){ref-type="fig"}). Dual color FISH was performed to confirm presence of the aberration. A probe specific for *CDKN2A* confirmed that the deletion encompassed subband 9p21 (Figure [2](#Fig2){ref-type="fig"}A). Finally, MCB9 probe set (Figure [2](#Fig2){ref-type="fig"}B) revealed the following karyotype: 46,XY,del(9)(p13) (20).Flow cytometric analysis of bone marrow specimen characterized this case as a T-PLL (Figures [3](#Fig3){ref-type="fig"}A-C). The abnormal cell population (97% of tested cells) was positive for CD45, CD2, CD4, CD7, and expressed CD5 heterogeneously and at low levels. Also the population was negative for TdT, CD1a, CD3, CD8, CD34, and HLA-DR.Figure 1**GTG-banding revealed a deletion of the short arm of a derivative chromosome 9 del(9)(p?).** A derivative chromosome is marker by arrowhead.Figure 2**Karyotype and chromosomal aberrations were confirmed using molecular cytogenetic approaches. (A)** The deletion of *CDKN2A* was identified on the der(9). **(B)** The application of MCB 9 characterized the del(9)(p13) comprehensively. Abbreviations: \# = chromosome; der = derivative chromosome.Figure 3**Flow cytometric dot plots showing the abnormal population of T-cells. (A)** dim CD45 expression. **(B)** CD4 expression. **(C)** CD2 and CD7 coexpression.

Discussion {#Sec8}
==========

T-PLL primarily affects older adults (median age at presentation, 61 years) with male predominance \[[@CR3]\] and is considered as an aggressive leukemia with poor or no response to therapy \[[@CR7]\].

T-cell CLL is now reclassified as T-PLL according to the WHO/revised form of European-American Classification of lymphoid neoplasm classification for lymphoid malignancies because of aggressive clinical behavior \[[@CR14]\]. T-PLL represents approximately 2% of all mature lymphocytic leukemia in adults and 3% of T-cell malignancies overall \[[@CR1], [@CR15]\].

Concerning the immunophenotype of the present case, it fits into the known picture of T-PLL. Immunphenotype of T-prolymphocytes is consistent with that of a mature post-thymic T-cell. As such it was negative for CD1a and TdT, but positive for pan T-cell markers, such as CD2, CD3, CD5, and CD7. CD7 is expressed with stronger intensity than seen in normal T-cells and other mature T-cell malignancies, but at levels comparable to those seen in T-acute lymphocytic leukemia (T-ALL) \[[@CR16]\]. Most of the cases (65%) have CD4+/CD8- cells, 21% of cases are CD4+/CD8+, and 13% of cases are CD4-/CD8+ \[[@CR17]\]. Surface expression of CD3 and TCR-α/ß may not be detected in up to 20% of cases, but their expression is always seen in the cytoplasm \[[@CR16]\].

As already mentioned T-PLL is a rare entity; here we describe a childhood T-PLL case with de novo del(9)(p13) leading to monoallelic deletion of the tumor suppressor gene *CDKN2A*. To the best of our knowledge, the present case is unique in two ways: it is the only one ever seen with this kind of aberration in a childhood case, and it is the only one with a del(9)(p13) as the sole aberration (for comparison see \[[@CR18]\]).

The most frequent chromosomal abnormalities in T-PLL include 14q11.2-aberrations involving TCR-region, and 11q-rearrangements leading to deletions of *ATM* or *MLL* genes. Other yet reported abnormalities involve various chromosomal regions like 5, 6, 8, 9p, 7q, 12p, 13q, 14q, 16q, 17, 21 and 22 \[[@CR8]--[@CR11], [@CR19], [@CR20]\].

T-PLL occurs in enhanced frequencies in ataxia telangiectasia (AT) families \[[@CR21]\]. This observation supports possible association between *ATM* mutations and T-PLL. Accordingly Friedenson \[[@CR22]\] described ATM mutations in 44-66% of T-PLL patients.

*CDKN2A* and *CDKN2B* are tumor suppressor genes located in 9p21. They belong to the family of inhibitors of cyclin-dependent kinases. *CDKN2A* gene encodes for the two proteins p14^ARF^ and p16^INK4a^, and the *CDKN2B* gene for p15 ^INK4b^ protein; all three are key regulators of G1 phase cell-cycle arrest and senescence \[[@CR23]\]. It has recently been observed that these genes are inactivated in a wide range of human cancers by epigenetic mechanisms \[[@CR23], [@CR24]\],

Loss of heterozygosity of chromosome arm 9p, including the *CDKN2A* locus, is one of the most frequent genetic events in childhood ALL, suggesting inactivation of the second allele or, possibly, haploinsufficiency \[[@CR25]\]. Haploinsufficiency of a tumor suppressor gene (e.g. *CDKN2A*), has been shown to be adequate to promote tumor progression \[[@CR26]\]. Homozygous deletion of *CDKN2A* has been suggested as the dominant mechanism of its inactivation in leukemogenesis \[[@CR27]\].

FOXA1 is a key transcription (TF) factor for *CDKN2A* expression \[[@CR24], [@CR28]\] and a member of fork head gene family. TFs have remarkable pioneering activities to open chromatin for its subsequent cooperation with DNA-interacting proteins, especially important during embryogenesis and organ development \[[@CR29], [@CR30]\].

Our case fulfills the clinical, cytogenetic, molecular cytogenetic and flow cytometry criteria for a T-PLL case. It is important to recognize T-PLL because it has a more aggressive clinical course than mature T-cell leukemia. As del(9)(p13) was the only cytogenetic aberration in this aggressive childhood T-PLL case alterations of *CDKN2A* gene may be an early or even the primary event in T-PLL formation.

Consent {#Sec9}
-------

Written informed consent was obtained from the patient for publication of this case report and accompanying images.
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